In this article
A new analysis of intrauterine devices (IUDs) has found that women who use this contraceptive method are significantly less likely to develop cervical cancer. Researchers reviewed data from 16 observational studies monitoring more than 12,000 women, and found that IUD users had approximately 36% lower rates of cervical cancer — the fourth most common cancer in women worldwide — compared to non-users.
Victoria Cortessis, an expert in preventive medicine at the University of Southern California, described the findings as striking: "The patterns we found are amazing, not at all so subtle. While making contraception decisions, the possibility that women may experience some cancer control help may be very influential." She and her team emphasize, however, that as a meta-analysis of observational studies, the research does not establish a causal relationship — and further investigation is needed before any formal recommendations can be made.
Researchers have proposed two possible mechanisms for the association. The first is that the physical presence of the IUD in the uterus stimulates a localized immune response in the cervix, which may help the body fight off existing human papillomavirus (HPV) infections — the cause of more than 70% of all cervical cancer cases. The second hypothesis is that when an IUD is removed, the scraping effect may simultaneously clear infected cells, potentially reducing the likelihood of cancerous tissue developing over time.
Importantly, researchers are clear that these findings should not be interpreted as a recommendation for women to use an IUD specifically to reduce cervical cancer risk. The most effective protection remains regular cervical cancer screening and HPV vaccination. As Cortessis told Newsweek: "Screening is everything. If a woman has a lifetime screening history, her risk is much lower." The IUD finding is a promising area for future research, but screening and vaccination remain the cornerstones of cervical cancer prevention.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.